Cui Bono? Finding Super Responders In Clinical Trials

I’m a voracious reader of mysteries in my spare time.  And some juncture in every story, as the detective finds himself staring at the corpse, they ask the inevitable question “Cui Bono — who benefits?”  Oddly enough, this is a question that doesn’t get asked often or early enough in the drug discovery and development process.

But that’s starting to change in translational medicine.  Recently, Memorial Sloan-Kettering launched an effort to identify so-called “super responders”.  These are patients whose disease went into remission after being given a drug or drug combination.  With the advent of low-cost whole genome- and tumor-sequencing, it’s now feasible to take a deeper look at the genomic characteristics of these super-responders in the hopes of being able to identify what makes them super-responders.  Ultimately, this information would be used to determine which patients are most likely to benefit from new treatments.


About aspenbio

I write software for scientists. I'm interested in Java/Groovy/Grails, the Semantic Web and Cancer Biology.
This entry was posted in Cancer Research, Drug Development, Informatics, pancreatic cancer and tagged , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s